H5N1 : "DÉJÀ VU ALL OVER AGAIN — REFUSING to LEARN the LESSONS of COVID-19"
H/t @falsel_net
The article warns that the US response to a potential H5N1 pandemic risks repeating the mistakes of COVID-19, with inadequate testing, coordination ...nejm.org/doi/full/10.10…
2) ... and political/legal constraints limiting public health measures.
Despite pandemic preparedness plans, the US struggled with COVID-19 due to overconfidence, fractured jurisdiction, and political polarization.
3) Similar issues now threaten the response to H5N1, as antivaccine sentiment, legal challenges, and congressional unwillingness to invest could impair the ability to rapidly scale countermeasures. The article urges health professionals to advocate for evidence-based policies ...
4) ...and investments to address weaknesses exposed by COVID-19 and prepare for future pandemics, which may look different from the last.
Thanks 🙏
• • •
Missing some Tweet in this thread? You can try to
force a refresh
When an ANCESTRAL SARS-CoV-2 VACCINE INDUCES ANTI-OMICRON ANTIBODIES !!!
One of the most interesting studies I have read, on the fascinating subject of "SOMATIC HYPERMUTATION" (SHM) nature.com/articles/s4146…
2) Somatic hypermutation is a crucial process in the adaptive immune response, where antibody-producing B cells rapidly accumulate random mutations in their antibody genes.
3) This allows the B cells to generate a diverse repertoire of antibodies, increasing the chances of recognizing and neutralizing new variants of a pathogen.
2) This study examined the relationship between US state-level COVID-19 restrictions and excess pandemic deaths. It found that states with stronger restrictions, such as mask requirements and vaccine mandates, experienced 10-21% fewer excess deaths compared to states with ...
3) ... with weaker restrictions. The analysis suggests that behavioral changes like increased masking and vaccination accounted for 49-79% of this difference.
What are the LONG-TERM NEUROLOGICAL and GASTROINTESTINAL SEQUELAE of COVID-19 COMPARED to OTHER VIRAL and BACTERIAL INFECTIONS, including influenza, herpes viruses, and Lyme disease ?
2) Using a large nationwide medical record database, the researchers found that while COVID-19 increased the risk of various neurological and GI symptoms compared to uninfected controls, many of these sequelae occurred at similar or even higher rates after other infections.
3) The notable exception was autonomic nervous system symptoms, which were significantly more common after COVID-19 than most infections studied. In contrast, sensory and motor nervous system symptoms were often more prevalent after infections like influenza and herpes zoster.
2) The optimal timing for annual COVID-19 booster shots varies by location, timed to precede seasonal infection peaks by 2-3 months. Delaying boosters even a few months can greatly reduce protection.
3) Breakthrough infections also impact optimal timing - those infected just before the yearly optimal date can stick to that schedule, while those infected 6-12 months after a booster can delay their next shot by a similar time to maximize protection.
LONG COVID : The Complex Relationship Between RECOVERY and REINFECTION
(3rd part)
Long COVID : SEIR model or "SAR(S)" model ?
2) SEIR is a mathematical model used to understand the spread of infectious diseases. It divides the population : susceptible (S), exposed (E), infectious (I), and recovered (R). It tracks the transitions between these compartments to simulate the disease dynamics.
3) I suggest a model for long COVID called the "SAR(S) model" :
▶️ "S": Represents those who are Susceptible to long COVID. This group includes a large percentage of the population, especially due to reinfections.
2) The recovery process for Long COVID is a multifaceted topic. This study I shared in May 2023 was among the initial studies to tackle this subject. More research will continue to emerge to further comprehend and explore this topic.
3) In this study researchers aimed to identify distinct trajectories in the evolution of post-COVID-19 condition over 2 years. They used data from a large prospective cohort of 2,197 patients in France to model symptom trajectories.